Genprex Inc Stock Price, News & Analysis

Genprex (NASDAQ: GNPX) announced the publication of their research collaborators' abstract in Cancer Research's online Proceedings supplement. The abstract, which will be presented at the 2025 AACR Annual Meeting, showcases positive preclinical data for Reqorsa® Gene Therapy in treating KRASG12C mutant non-small cell lung cancer (NSCLC).

The research demonstrates that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy, particularly when combined with sotorasib in resistant tumors.

Genprex announced that its research collaborators will present positive preclinical data for Reqorsa® Gene Therapy at the 2025 AACR Annual Meeting in Chicago. The study focuses on treating KRASG12C mutant non-small cell lung cancer (NSCLC), particularly addressing resistance to Lumakras® (sotorasib).

The preclinical data demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy both as a standalone therapy and in combination with sotorasib in resistant tumors.

Genprex (NASDAQ: GNPX) announced that its research collaborators will present positive preclinical data for GPX-002, their diabetes gene therapy drug candidate, at the 2025 American Diabetes Association 85th Scientific Sessions in Chicago.

GPX-002 is being developed as a potential disease-modifying therapy for both Type 1 and Type 2 diabetes, aiming to eliminate the need for daily blood glucose monitoring and insulin replacement therapy. Recent company developments include:

• Signing an amended license agreement for multiple diabetes gene therapy technologies
• Formation of Convergen Biotech subsidiary focused on diabetes program development
• Addition of research on re-dosable non-viral delivery systems

Two presentations are scheduled: a poster presentation on lipid nanoparticles for islet cell transfection, and an oral presentation on AAV-mediated gene therapy treatment in non-human primates with streptozotocin-induced diabetes.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, has announced its participation in BIO Europe Spring 2025, scheduled for March 17-19 in Milan, Italy. Ryan Confer, President and CEO, and Thomas Gallagher, Senior VP of Intellectual Property and Licensing, will represent the company.

The executives will be available for one-on-one meetings with industry groups to discuss Genprex's gene therapies for cancer and diabetes. The conference is expected to attract over 3,700 executives from biotech, pharma, and finance sectors, facilitating more than 20,000 one-on-one meetings.

Interested parties can schedule meetings through the conference portal or by contacting Genprex's Investor Relations at investors@genprex.com.

Genprex (NASDAQ: GNPX) announced advancement in its diabetes program through a strategic collaboration with a CDMO partner to research a non-viral lipid nanoparticle delivery system for its diabetes gene therapy drug candidate. This alternative approach represents a second-generation development, separate from existing preclinical programs.

The company's current diabetes treatment, GPX-002, uses an AAV vector containing Pdx1 and MafA genes administered into the pancreatic duct. While effective, viral delivery systems cannot be readministered due to immune responses. The non-viral approach could enable multiple treatments, potentially optimizing patient outcomes.

Recent preclinical studies showed GPX-002's effectiveness in Type 1 NOD mouse models, maintaining glucose control for approximately 120 days, significantly longer than the 17-day median observed with traditional islet cell transplants. The therapy is being developed for both Type 1 and Type 2 diabetes, working by transforming pancreatic alpha cells into functional beta-like cells.

Genprex (NASDAQ: GNPX) has announced significant developments in its diabetes gene therapy program. The company has signed an amended exclusive license agreement with the University of Pittsburgh, consolidating multiple technologies for Type 1 and Type 2 diabetes gene therapy. The agreement covers worldwide exclusive rights to patent applications and technologies related to gene therapy using Pdx1 and MafA transcription factors.

The company has also formed Convergen Biotech, a wholly-owned subsidiary focused on diabetes program development. Their gene therapy product, GPX-002, is designed to transform pancreatic alpha cells into functional beta-like cells for T1D treatment and rejuvenate exhausted beta cells for T2D treatment. The therapy is administered via routine endoscopy into the pancreatic duct.

Genprex plans to seek FDA guidance for preclinical studies needed for IND application by the second half of 2025. The separation of the diabetes program into Convergen Biotech aims to expedite clinical development and enable potential direct investment and strategic collaboration.

Genprex (NASDAQ: GNPX) announced new research findings showing that NPRL2 gene therapy, using their Oncoprex® Delivery System, demonstrates significant potential in treating anti-PD1 resistant non-small cell lung cancer (NSCLC). The study, published in eLife, revealed that NPRL2 treatment alone showed dramatic antitumor effects in KRAS/STK11 double mutant NSCLC xenografts, while pembrolizumab (Keytruda®) alone was ineffective.

The research utilized Genprex's non-viral ONCOPREX Delivery System, which uses lipid nanoparticles to deliver tumor suppressor genes intravenously. The study demonstrated stronger antitumor effects in humanized mice compared to non-humanized NSG mice, indicating that NPRL2's effectiveness works through immune system activation. This breakthrough could potentially target approximately 30% of NSCLCs with KRAS mutations.

Genprex (NASDAQ: GNPX) has announced the dosing of the first patient in the Phase 2 expansion portion of its Acclaim-3 clinical study, evaluating Reqorsa® Gene Therapy combined with Tecentriq® as maintenance therapy for extensive stage small cell lung cancer (ES-SCLC).

The Phase 2 expansion will enroll 50 patients across 10-15 U.S. sites, with an interim analysis planned after the first 25 patients reach 18 weeks of follow-up, expected in the second half of 2025. The study's primary endpoint is to determine the 18-week progression-free survival rate.

Current ES-SCLC patients have a median progression-free survival of 5.2 months, with those receiving Tecentriq maintenance therapy showing 2.6 months. The treatment combination has received both FDA Fast Track and Orphan Drug Designations. Preclinical data from October 2023 showed the combination therapy provided better tumor control than either agent alone.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco. The company's executive team, including Ryan Confer (President, CEO, and CFO), Dr. Mark Berger (Chief Medical Officer), and Thomas Gallagher (SVP of Intellectual Property and Licensing), will attend the conference.

The executives will be available for one-on-one meetings with industry and investor groups to discuss Genprex's gene therapies for cancer and diabetes. Interested parties can schedule meetings through Investor Relations at investors@genprex.com.